Jerusalem, Israel, February 09 2021 – Vidac Pharma Ltd announces inclusion of the first Patient in a Placebo controlled Phase II study in early forms of Cutaneous T-Cell Lymphoma treated with its first in class drug VDA 1102 . VDA 1102 disrupt the binding of the glycolytic enzyme HK2 over expressed in Cancer Cells from the VDAC channel. This causes returning of Apoptosis (programmed death) and cell environment and functions to normal behavior. VDA 1102 does not affect normal cells. This clinical trial takes place under the direction of Prof. Emilia Hodak, head of Dermatology at Rabin Center (Beilinson) in Petach Tikva. Israel.
About Vidac Pharma
Vidac is a privately-held clinical-stage oncology-focused biopharmaceutical company developing first-in-class drugs using its breakthrough metabolic immuno-oncology platform technology. Vidac is using its proprietary HEXAGON™ bioinformatics tool to identify patients with cancers that have high HK2 levels, across a variety of tumor types. Vidac’s lead drug, VDA-1102 ointment, is in Phase 2b for treatment of Actinic Keratosis, an early form of cutaneous SCC. VDA-1102 is also being developed in a parenteral form for the treatment of solid tumors and hematological malignancies, as monotherapies and in combination.
For more information regarding Vidac Pharma, please visit www.vidacpharma.com.
Contact: Max Herzberg +972-54-425-7381
###